Sinopia Biosciences, Inc., a computational drug discovery company, received a Therapeutic Pipeline Program research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support advancement of its patent-protected small molecule (SB-0107) for motor and non-motor symptoms of Parkinson’s disease. SB-0107 is Sinopia’s lead therapeutic candidate identified through the company’s proprietary machine learning and network biology platform. The grant will advance research of SB-0107 with levodopa towards clinical trials.
Parkinson’s disease is a progressive neurological condition affecting about 7 million people worldwide. Levodopa remains the gold-standard treatment for Parkinson’s disease patients but has long-term liabilities including dyskinesia and loss of efficacy (motor fluctuations). There is a strong unmet need for novel therapies that avoid or delay these adverse effects.
Evaluating a computationally identified candidate in advanced preclinical models is a strong validation of the predictive capabilities of Sinopia’s computational platform. SB-0107 in preclinical models shows very robust anti-Parkinsonian activity without causing or exacerbating levodopa induced-dyskinesia. These results, coupled with its unique mechanism of action, make SB-0107 a promising clinical candidate to change how Parkinson’s disease is treated at all stages of disease.
About Sinopia Biosciences
Sinopia Biosciences, Inc. is a San Diego based computational drug discovery company located at JLABS San Diego that is enabling safer therapeutics. Sinopia’s proprietary computational platform combines high-throughput omics data, machine learning, and network biology to identify therapeutic cnadiates that avoid or treat side effects of key life changing drug classes. Sinopia’s lead program is in Parkinson’s disease.